Evaluation of Effectiveness of Two Different Doses of Mivacurium in Rapid Sequence Intubation

• Status: Recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Mivacurium can be considered as an optimal choice for muscle relaxation in short duration surgeries, as butyrylcholinesterase can rapidly and reliably degrade this benzylisoquinoline muscle relaxant in vivo. However the histamine release related to a rapid high-dose injection, unsatisfactory intubation conditions and unexpected delay in recovery in patients may be encountered with butyrylcholinesterase deficiency

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Al-Azhar University
• Treatments: Mivacurium

Criteria

Inclusion Criteria:

• 20-60 year old patients.

• American society of anaesthesia (ASA) 1 and 2.

• Emergency surgery.

Exclusion Criteria:

• Refusal.

• allergy.

• neuromuscular disease.

• Suspected desaturation.

• Severe cardiac disease.

• Severe pulmonary disease.